文献速递白血病淋巴瘤浆细胞疾病

OT-82:靶向血液肿瘤对NAD生物合成强依赖的新型抗癌候选药物

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
PubMed 文献 · Leukemia · 2020-01-02

研究通过化学库筛选和先导优化发现小分子OT-82,在体外和小鼠异种移植模型中对多种血液肿瘤有强效,包括急性和淋巴细胞白血病、红白血病、多发性骨髓瘤和伯基特淋巴瘤。OT-82通过抑制NAMPT诱导细胞死亡,对患者来源白血病细胞比健康骨髓造血前体更毒,且在 mice 和 nonhuman primates 中未显示其他NAMPT抑制剂的心脏、神经或视网膜毒性,主要剂量限制毒性为造血和淋巴器官。

要点

  • OT-82在体外和小鼠模型中强效抑制多种血液肿瘤,包括儿童和成人白血病。
  • OT-82对患者来源白血病细胞毒性高于健康骨髓造血前体。
  • OT-82通过抑制NAMPT诱导细胞死亡,主要剂量限制毒性为造血和淋巴器官。

核心结论

  • 血液肿瘤细胞对NAMPT存在强依赖,OT-82是有前景的血液肿瘤治疗候选药物。

研究设计与样本

  • 研究通过化学库筛选和先导优化鉴定OT-82,并在体外、小鼠异种移植模型、患者来源细胞及小鼠和非人灵长类毒性研究中评估。

主要发现

  • OT-82在体外和小鼠异种移植模型中对急性髓系和淋巴细胞白血病、红白血病、多发性骨髓瘤及伯基特淋巴瘤有强效。
  • OT-82对患者来源白血病细胞的毒性高于健康骨髓造血前体。
  • OT-82通过抑制NAMPT诱导细胞死亡,NAMPT是NAD补救合成途径的限速酶。
  • 在小鼠中优化OT-82剂量和饮食烟酸可扩大治疗指数。
  • 在小鼠和非人灵长类中,OT-82未显示其他NAMPT抑制剂的心脏、神经或视网膜毒性,对小鼠衰老或寿命无影响。

临床怎么用

  • OT-82作为NAMPT抑制剂候选药物,需进一步临床研究评估其在血液肿瘤中的疗效和安全性。

局限性

  • 研究主要为临床前体外和动物模型数据,尚未在人体中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Effective treatment of some types of cancer can be achieved by modulating cell lineage-specific rather than tumor-specific targets. We conducted a systematic search for novel agents selectively toxic to cells of hematopoietic origin. Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. OT-82 was also more toxic towards patients-derived leukemic cells versus healthy bone marrow-derived hematopoietic precursors. OT-82 was shown to induce cell death by inhibiting nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the salvage pathway of NAD synthesis. In mice, optimization of OT-82 dosing and dietary niacin further expanded the compound's therapeutic index. In toxicological studies conducted in mice and nonhuman primates, OT-82 showed no cardiac, neurological or retinal toxicities observed with other NAMPT inhibitors and had no effect on mouse aging or longevity. Hematopoietic and lymphoid organs were identified as the primary targets for dose limiting toxicity of OT-82 in both species. These results reveal strong dependence of neoplastic cells of hematopoietic origin on NAMPT and introduce OT-82 as a promising candidate for the treatment of hematological malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Korotchkina L, Kazyulkin D, Komarov PG, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020. PMID: 31896781. doi:10.1038/s41375-019-0692-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。